794P Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC)
JM Ressler, A Kusienicka, R Silmbrod… - Annals of …, 2022 - annalsofoncology.org
Background Cutaneous basal cell carcinomas (BCCs) carry a high mutational burden and
are accompanied by a regulatory T-cell-rich tumor microenvironment, which makes them an
attractive target for oncolytic virotherapy. This is the first clinical trial to report data on the
efficacy of Talimogene laherparepvec (T-VEC) in BCCs. We hypothesized that neoadjuvant
treatment with T-VEC can reduce the size of difficult to resect primary BCCs to allow surgery
without skin grafts or skin flaps. Methods In this exploratory phase II study, 18 patients (11 …
are accompanied by a regulatory T-cell-rich tumor microenvironment, which makes them an
attractive target for oncolytic virotherapy. This is the first clinical trial to report data on the
efficacy of Talimogene laherparepvec (T-VEC) in BCCs. We hypothesized that neoadjuvant
treatment with T-VEC can reduce the size of difficult to resect primary BCCs to allow surgery
without skin grafts or skin flaps. Methods In this exploratory phase II study, 18 patients (11 …
以上显示的是最相近的搜索结果。 查看全部搜索结果